Ali Sever
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Sever has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Aaditya Prakash Sinha
School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK
2 shared publications - Arnie Purushotham
School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
2 shared publications Georgina Bitsakou
Guy's and St Thomas’ Hospitals NHS Trust, London, UK
2 shared publicationsAbdul Kasem
Department of Surgery, Princess Royal University Hospital, King’s College Hospital NHS Foundation Trust, Orpington, UK
1 shared publicationAnna Metafa
Breast Unit, King’s College Hospital NHS Foundation Trust, London, United Kingdom
1 shared publication- Anna Metafa
Department of Radiology, Princess Royal University Hospital, King’s College Hospital NHS Foundation Trust, Orpington, UK
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102045
Development and evaluation of AI-based clinical decision support system for streamlining breast multidisciplinary team meetings
Objectives: Multidisciplinary team (MDT) meetings are key to delivering cancer care. Increasing caseload and limited resources make them less effective and unsustainable. The aim of this quality improvement project was to assess novel artificial intelligence-based clinical decision support (CDS) technology to develop and validate standard of care (SoC) to streamline the breast MDT meetings in a tertiary cancer centre. Methods: A clinical governance group of the MDT approved international guidelines used to develop SoC. Deontics CDS was assessed for its suitability to apply the SoC pathway for benign and malignant breast disease with the exclusion of metastatic and recurrent cancer. Results: Patients discussed over the preceding 16 months were added to the platform in cohorts of 50 women: two consisting of 50 women each diagnosed with benign disease (benign A and B: n=100) and three consisting of 50 women each diagnosed with malignant disease (cancer A, B and C: n=150). Concordance between the blinded MDT decision outcomes and SoC recommendations was analysed. This stepwise approach identified knowledge gaps in SoC and refined the CDS. Concordance improved from 82% to 100% in benign and from 94% to 100% in malignant cases. Discussion: A sequential process of validating the SoC with data derived from the development of evidence-based SoC protocols based on international guidelines resulted in a final 100% concordance rate between the platform and MDT recommendations for both benign and malignant disease. Conclusions: CDS technology could be a milestone in using SoC to deliver a sustainable clinical decision pathway.
- 19 August 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102045
Open AccessDevelopment and evaluation of AI-based clinical decision support system for streamlining breast multidisciplinary team meetings
Objectives: Multidisciplinary team (MDT) meetings are key to delivering cancer care. Increasing caseload and limited resources make them less effective and unsustainable. The aim of this quality improvement project was to assess novel artificial intelligence-based clinical decision support (CDS) technology to develop and validate standard of care (SoC) to streamline the breast MDT meetings in a tertiary cancer centre. Methods: A clinical governance group of the MDT approved international guidelines used to develop SoC. Deontics CDS was assessed for its suitability to apply the SoC pathway for benign and malignant breast disease with the exclusion of metastatic and recurrent cancer. Results: Patients discussed over the preceding 16 months were added to the platform in cohorts of 50 women: two consisting of 50 women each diagnosed with benign disease (benign A and B: n=100) and three consisting of 50 women each diagnosed with malignant disease (cancer A, B and C: n=150). Concordance between the blinded MDT decision outcomes and SoC recommendations was analysed. This stepwise approach identified knowledge gaps in SoC and refined the CDS. Concordance improved from 82% to 100% in benign and from 94% to 100% in malignant cases. Discussion: A sequential process of validating the SoC with data derived from the development of evidence-based SoC protocols based on international guidelines resulted in a final 100% concordance rate between the platform and MDT recommendations for both benign and malignant disease. Conclusions: CDS technology could be a milestone in using SoC to deliver a sustainable clinical decision pathway.
- 17 March 2026
- Published by Elsevier in Clinical Radiology
- Vol. 97, 107313
Double reading mammograms in the symptomatic setting
- 17 March 2026
- Published by Elsevier in Clinical Radiology
- Vol. 97, 107313
Double reading mammograms in the symptomatic setting
- Open Access
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (2) , e240138
Tumor Biomechanics Quantified Using MR Elastography to Predict Response to Neoadjuvant Chemotherapy in Individuals with Breast Cancer
Assessment of tumor biomechanics through MR elastography improved the identification of complete responders among individuals with breast cancer undergoing neoadjuvant chemotherapy.
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 7 (2) , e240138
Open AccessTumor Biomechanics Quantified Using MR Elastography to Predict Response to Neoadjuvant Chemotherapy in Individuals with Breast Cancer
Assessment of tumor biomechanics through MR elastography improved the identification of complete responders among individuals with breast cancer undergoing neoadjuvant chemotherapy.
- 13 March 2024
- Published by SAGE Publications in Ultrasound
- Vol. 32 (4) , 291-295
Two cases of breast pseudoaneurysm following core biopsy: A very rare complication with different treatment options
Introduction: Breast pseudoaneurysm is a rare complication following breast interventional procedures such as core biopsies and vacuum-assisted biopsies. The occurrence of pseudoaneurysm increases with the conditions of increased breast vascularity like cancer, pregnancy and lactation. Case Report: We present two cases of pseudoaneurysm formation secondary to core biopsies of the breasts. The first patient was an 82-year-old female patient who presented with breast swelling and bruising after multiple clinical core biopsies of the left breast. Our second patient was a 47-year-old lady who presented with a palpable lump following ultrasound-guided core biopsies of the left breast. Ultrasound showed hypoechoic pulsating area with evidence of internal colour flow in connection with a vessel in both cases. Imaging appearances were in keeping with a pseudoaneurysm of the breast. Discussion: Most pseudoaneurysms are secondary to interventional procedures in the breast. Common clinical presentation is a pulsatile, palpable mass at the biopsy site soon after the biopsy or later. On B mode imaging, it presents as a well-circumscribed mass of mixed echogenicity. Typical waveform in spectral Doppler and ‘yin-yang’ sign in colour Doppler is demonstrated with a turbulent internal flow. There are different treatment options to manage pseudoaneurysms of the breast. Conclusion: Pseudoaneurysm of the breast should be considered if a patient presents with a breast mass/lump close to a recent biopsy site. On clinical examination, pulsatility of the mass should raise the suspicion and definite diagnosis can be made with spectral and colour Doppler US scan.
- 13 March 2024
- Published by SAGE Publications in Ultrasound
- Vol. 32 (4) , 291-295
Two cases of breast pseudoaneurysm following core biopsy: A very rare complication with different treatment options
Introduction: Breast pseudoaneurysm is a rare complication following breast interventional procedures such as core biopsies and vacuum-assisted biopsies. The occurrence of pseudoaneurysm increases with the conditions of increased breast vascularity like cancer, pregnancy and lactation. Case Report: We present two cases of pseudoaneurysm formation secondary to core biopsies of the breasts. The first patient was an 82-year-old female patient who presented with breast swelling and bruising after multiple clinical core biopsies of the left breast. Our second patient was a 47-year-old lady who presented with a palpable lump following ultrasound-guided core biopsies of the left breast. Ultrasound showed hypoechoic pulsating area with evidence of internal colour flow in connection with a vessel in both cases. Imaging appearances were in keeping with a pseudoaneurysm of the breast. Discussion: Most pseudoaneurysms are secondary to interventional procedures in the breast. Common clinical presentation is a pulsatile, palpable mass at the biopsy site soon after the biopsy or later. On B mode imaging, it presents as a well-circumscribed mass of mixed echogenicity. Typical waveform in spectral Doppler and ‘yin-yang’ sign in colour Doppler is demonstrated with a turbulent internal flow. There are different treatment options to manage pseudoaneurysms of the breast. Conclusion: Pseudoaneurysm of the breast should be considered if a patient presents with a breast mass/lump close to a recent biopsy site. On clinical examination, pulsatility of the mass should raise the suspicion and definite diagnosis can be made with spectral and colour Doppler US scan.
- Open Access
- 1 June 2013
- Published by S. Karger AG in Breast Care
- Vol. 8 (3) , 199-202
How Long Will I Be Blue? Prolonged Skin Staining Following Sentinel Lymph Node Biopsy Using Intradermal Patent Blue Dye
Background: Blue dye used for sentinel lymph node biopsy (SLNB) in breast cancer patients may cause prolonged skin discoloration at the site of injection. The aim of this study was to assess the duration of such skin discoloration. Patients and Methods: 236 consecutive patients who had undergone breast conserving surgery and SLNB for breast cancer were reviewed prospectively from January 2007 to December 2009. Results: Of the 236 patients, 2 had undergone bilateral surgery, and 41 had been examined in consecutive yearly reviews. Blue discoloration remained visible at the injection site after 12, 24, and > 36 months in 36.5, 23.6, and 8.6% of the patients, respectively. Conclusion: The use of patent blue for identification of the sentinel lymph node in patients undergoing breast cancer surgery may result in prolonged discoloration of the skin at the injection site.
- 1 June 2013
- Published by S. Karger AG in Breast Care
- Vol. 8 (3) , 199-202
Open AccessHow Long Will I Be Blue? Prolonged Skin Staining Following Sentinel Lymph Node Biopsy Using Intradermal Patent Blue Dye
Background: Blue dye used for sentinel lymph node biopsy (SLNB) in breast cancer patients may cause prolonged skin discoloration at the site of injection. The aim of this study was to assess the duration of such skin discoloration. Patients and Methods: 236 consecutive patients who had undergone breast conserving surgery and SLNB for breast cancer were reviewed prospectively from January 2007 to December 2009. Results: Of the 236 patients, 2 had undergone bilateral surgery, and 41 had been examined in consecutive yearly reviews. Blue discoloration remained visible at the injection site after 12, 24, and > 36 months in 36.5, 23.6, and 8.6% of the patients, respectively. Conclusion: The use of patent blue for identification of the sentinel lymph node in patients undergoing breast cancer surgery may result in prolonged discoloration of the skin at the injection site.